Evaluation of Cellular Immunity in SARS-CoV-2 recovered subjects as an alternative to IgG testing - NI

Atrimed Biotech LLP0 sites60 target enrollmentStarted: TBDLast updated: October 17, 2022

Trial Snapshot

No summary available.

•1) Both male and female adult populations aged from 18 to 60 years with background comorbidities such as Type II Diabetes mellitus(DM), hypertension(HTN), Bronchial asthma, Ischemic heart disease(IHD), cerebrovascular accidents(CVA), Thyroid disorders will be included in the study.
•2) Convalescent, RTPCR negative for SARS-CoV2 ( 2 weeks), IgG positive for SARS CoV2 , asymptomatic patients as determined by the principal investigator/ physician.
•3) SARS CoV2 frontline workers are included as test subjects.
•4) Non health care workers are included as control subjects. 5) Volunteer is willing and able to comply with all the trial requirements. 5) All volunteers obtained written informed consent form in English as well as native language, Kannada

•1) Patients with active COVID-19 infection( PCR positive, IgM positive).
•2) Known patients of HIV, Hepatitis-B/C , H1N1.
•3) Pregnant and lactating women.
•4) Patients with known autoimmune diseases on immuno-suppressants and steroids.
•5) Patients who have participated in another clinical trial within the previous 30 days.
•6) Patient not willing to give informed consent form

Sponsor

Atrimed Biotech LLP